CDKN2A Polyclonal Antibody

Background:
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53.

Research Area: Cancer, Cell Biology, Epigenetics and Nuclear Signaling

Synonyms:
CCM2, CDK4 inhibitor p16 INK4, CDK4I, CDKN2, CDKN2A, Cell cycle negative regulator beta, CMM2, Cyclin dependent kinase 4 inhibitor A, Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4), Cyclin Dependent Kinase Inhibitor 2A, Cyclin dependent kinase inhibitor 2A isoform 4, Cyclin dependent kinase inhibitor 2A isoforms 1/2/3, Cyclin dependent kinase inhibitor p16, INK4, INK4A, MLM, MTS1, Multiple tumor suppressor 1, p14, p16, P16INK4, p16INK4a, p19, p19Arf, TP16

Immunogen: Synthetic peptide of human CDKN2A

Swissprot: P42771
Gene Accession: NP000068

Purification Method: Antigen affinity purification

Buffer: PBS with 0.05% NaN3 and 40% Glycerol, pH7.4

Concentration: 0.4 mg/mL
Dilution: IHC 1:50-1:200, ELISA 1:1000-1:5000

Storage:
Store at -20°C. Avoid freeze / thaw cycles.